Abstract:ABSTRACT Diet and gut microbiota impact the progression of non-alcoholic steatohepatitis (NASH). An unhealthy diet, rich in fat and sugar, promotes gut microbiota dysbiosis, leading to the translocation of lipopolysaccharides (LPS) and other harmful pathogen-associated molecular patterns to the liver, triggering hepatic inflammation and aggravating NASH. Currently, there are no approved pharmacological treatments for NASH, although novel drugs, such as obeticholic acid (OCA), have demonstrated beneficial effects. Healthy dietary modifications have been proposed to prevent and treat NASH. However, the therapeutic effect of the combined implementation of a healthy dietary intervention with pharmaceutical agents or dietary supplements for NASH treatment and how it interplays with the gut microbiota and associated pathways remains poorly understood. This study aims to investigate the therapeutic efficacy of a healthy dietary modification, either alone or in combination with a dietary supplement [ginger essential oil (GEO)] or drug (OCA), in a Gubra-Amylin diet-induced NASH mouse model. NASH was induced for 12 weeks, after which the interventions were administered for a subsequent 3-week period. Our findings revealed that healthy dietary intervention primarily restores obesity, lipidemia, and NASH. In contrast, GEO and OCA have additional benefits by suppressing pro-inflammatory cytokines by partially modulating the NLRP3/ASC/caspase-1 pathways. Moreover, healthy dietary intervention restores gut microbiota composition and function from dysbiosis, while GEO and OCA partially mediate the gut-derived LPS/toll-like receptor 4/nuclear factor kappa B pathway. Therefore, adherence to healthy dietary patterns plays a primary role in NASH reversion, and additional supplementation of GEO or OCA could offer extra benefits in suppressing hepatic inflammation and preventing disease progression. IMPORTANCE The link between gut microbiota and diet is crucial in the development of non-alcoholic steatohepatitis (NASH). This study underscores the essential role of a healthy diet in preventing and treating NASH by reversing obesity, lipidemia, and gut microbiota dysbiosis. Moreover, the supplementation of functional food or drug to the diet can provide additional advantages by inhibiting hepatic inflammation through the modulation of the hepatic inflammasome signaling pathway and partially mediating the gut microbiota and lipopolysaccharide signaling pathway. This study highlights the importance of adopting healthy dietary habits in treating NASH and proposes that supplementing with ginger essential oil or obeticholic acid may offer additional benefits. Nonetheless, further clinical studies are necessary to validate these findings.

Is the Mediterranean diet a good preventive measure for NASH?

Nuts and Non-Alcoholic Fatty Liver Disease: Are Nuts Safe for Patients with Fatty Liver Disease?

Statins: An Under-Appreciated Asset for the Prevention and the Treatment of NAFLD or NASH and the Related Cardiovascular Risk

Mediterranean-Oriented Dietary Intervention Is Effective to Reduce Liver Steatosis in Patients with Nonalcoholic Fatty Liver Disease: Results from an Italian Clinical Trial

The role of Ursodeoxycholic acid in non-alcoholic steatohepatitis: a systematic review

Non-Alcoholic Steatohepatitis Patient Characterization and Real-World Management Approaches in Italy

Healthy diet intervention reverses the progression of NASH through gut microbiota modulation

Non-alcoholic fatty liver disease and steatohepatitis: State of the art on effective therapeutics based on the gold standard method for diagnosis

Efficacy and safety of drugs for nonalcoholic steatohepatitis

Anti-Angiogenic Effects of Natural Compounds in Diet-Associated Hepatic Inflammation

Non-invasive biomarkers prognostic of decompensation events in NASH cirrhosis: a systematic literature review

Current and emerging pharmacological options for the treatment of nonalcoholic steatohepatitis

Impact of a Mediterranean diet on hepatic and metabolic outcomes in non‐alcoholic fatty liver disease: The MEDINA randomised controlled trial

Anti-diabetic drugs and NASH: from current options to promising perspectives

Emerging Therapies for Non-Alcoholic Steatohepatitis (NASH): A Comprehensive Review of Pharmacological and Non-Pharmacological Approaches

Impact of current treatments on liver disease, glucose metabolism and cardiovascular risk in non-alcoholic fatty liver disease (NAFLD): a systematic review and meta-analysis of randomised trials

Endpoints in NASH Clinical Trials: Are We Blind in One Eye?

Current Therapeutical Approaches Targeting Lipid Metabolism in NAFLD

Nutraceutical Approach to Non-Alcoholic Fatty Liver Disease (NAFLD): The Available Clinical Evidence

Current and future therapeutic regimens for nonalcoholic fatty liver disease and nonalcoholic steatohepatitis

Non-alcoholic Steatohepatitis in Asians: Current Perspectives and Future Directions